Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 571-skin-debridement-with-cc
    Ask Trek AI about this page

    Skin Debridement with CC: Inpatient Reimbursement Overview

    DRG 571 addresses inpatient admissions for skin debridement procedures with a Complication or Comorbidity present, encompassing management of complex or infected wounds that require surgical removal of tissue. This Diagnosis-Related Group matters for inpatient reimbursement because the Complication or Comorbidity status increases expected resource use and influences Medicare prospective payment classification.

    Customize your policy alerts

    Sign up for drg 571 policy alerts

    Get alerted when payer policies referencing 571 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 571 Overview

    DRG 571 covers inpatient hospital admissions primarily for extensive skin debridement when a Complication or Comorbidity is present, including surgical removal of necrotic or infected tissue and management of complex wounds. This Diagnosis-Related Group captures cases with additional clinical complexity that increase resource use compared with non-Complication or Comorbidity cases. It matters for Medicare payment because the presence of a Complication or Comorbidity adjusts relative resource classification and influences prospective payment rates. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and therefore affect reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute procedural intervention trials focusing on optimized debridement techniques: randomized or prospective cohort studies compare different operative approaches (sharp surgical debridement, hydrosurgical systems, enzymatic adjuncts) or perioperative wound care protocols in hospitalized patients with extensive necrotic or infected skin and soft-tissue involvement. These studies enroll adults admitted for inpatient debridement with complicating comorbidities such as diabetes, peripheral vascular disease, or immunosuppression and measure short-term endpoints like removal of devitalized tissue, intraoperative blood loss, procedure time, and early infectious control. Results are relevant to surgeons and hospital payers because procedure selection and efficiency directly affect length of stay, complication rates, and resource utilization under DRG payment models.
    • Comparative effectiveness and infection-management research evaluating antimicrobial strategies and adjunctive therapies: pragmatic trials or observational comparative studies assess systemic antibiotic regimens, topical antimicrobial dressings, negative-pressure wound therapy initiation timing, or combinations thereof in patients undergoing skin debridement with underlying cellulitis or deep tissue infection. Populations include medically complex inpatients (e.g., chronic ulcers, surgical site infections, diabetic foot infections) where the question is which infection-control strategy reduces reoperation, readmission, and progression to limb-threatening infection. Findings inform antibiotic stewardship, device and supply use, and discharge planning decisions that impact both clinical outcomes and cost drivers important to hospitals and payers under DRG-based reimbursement.
    • Post-discharge outcomes and care-transition studies addressing rehabilitation, wound healing trajectories, and readmission prevention: prospective cohort studies or randomized care-pathway trials examine structured discharge bundles, home health nurse follow-up, or outpatient wound clinic timing for patients discharged after inpatient debridement, tracking wound closure rates, functional recovery, and 30–90 day readmissions. These studies target patients with complex social needs, comorbidity burden, or chronic wounds who are at high risk of delayed healing or recurrent infection. Results are critical for payers and providers because improvements in post-discharge management can shorten overall episode costs, reduce readmissions that affect DRG performance metrics, and guide investments in post-acute services and care coordination.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

    Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.